Immatics and BMS enter into global exclusive license for Immatics’ TCR Bispecific Program IMA 401.
Under the terms of the agreement, Immatics will receive an upfront payment of $150 million as well as up to $770 million in development, regulatory and commercial milestone payments, in addition to tiered double-digit royalty payments on net sales of IMA 401. Immatics retains the options to co-fund U.S. development in exchange for enhanced U.S. royalty payments and/or to co-promote IMA 401 in the US.
Immatics entered a strategic collaboration in 2019 with Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company (BMS) to develop novel adoptive cell therapies. This new collaboration to develop Immatics’ Bispecific candidate TCER IMA 401 complements ongoing cell therapy activities - both therapeutic modalities built on Immatics’ capabilities to identify novel targets and develop high-affinity, target-specific TCRs. The terms of the current agreement regarding Immatics’ TCER IMA 401 program exclude any MAGEA4/8 targets for cell therapy. The agreement is subject to customary clearance by antitrust regulators.
Related news and insights
Scynexis, Inc. announced that the FDA has approved a second indication for Bexafemme (ibrexafungerp tablets) for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC)
Eli Lilly and Company has announced that donanemab met all primary and secondary endpoints for the 6-month primary outco me analysis in the Phase III TRAILBLAZER-ALZ 4 study , providing the first active comparator data on amyloid plaque clearance in patients with early symptomatic Alzheimer's disease treated with amyloid-targeting therapies